Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials

<b>Objective</b> : Gefitinib, a small molecule tyrosine kinase inhibitor, showed a substantial effect as a salvage treatment for patients with advanced non-small cell lung cancer (NSCLC) who had failed prior chemotherapy. Subsequent phase III trials in previously untreated patients have...

Full description

Bibliographic Details
Main Author: Ibrahim Ezzeldin
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2010-01-01
Series:Annals of Thoracic Medicine
Subjects:
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2010;volume=5;issue=3;spage=153;epage=160;aulast=Ibrahim